

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**


Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

### **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Vertex Pharmaceuticals	All Wales Therapeutics and Toxicology
(deutivacaftor, tezacaftor, vanzacaftor)	Centre
,	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Asthma and Lung UK	Wales
CF Voices	British National Formulary
Cystic Fibrosis Care	Care Quality Commission
Cystic Fibrosis Trust	Department of Health - Northern Ireland
Gene People	Healthcare Improvement Scotland
Genetic Alliance	Medicines and Healthcare products
<ul> <li>NARA – The Breathing Charity</li> </ul>	Regulatory Agency
<ul> <li>South Asian Health Foundation</li> </ul>	<ul> <li>National Association of Primary Care</li> </ul>
Specialised Healthcare Alliance	<ul> <li>National Pharmacy Association</li> </ul>
	NHS Confederation
Healthcare professional groups	Scottish Medicines Consortium
Association for Respiratory	Welsh Government
Technology and Physiology	<ul> <li>Welsh Health Specialised Services</li> </ul>
Association of Chartered	Committee
Physiotherapists in Cystic Fibrosis	
Association of Genetic Nurses and	Possible comparator companies
Counsellors	Vertex Pharmaceuticals (elexacaftor, ,
<ul> <li>Association of Respiratory Nurse Specialists</li> </ul>	lumcaftor and ivacaftor)
British Dietetic Association	Relevant research groups
British Geriatrics Society	British Association for Lung Research
British Inherited Metabolic Disease	Cochrane Airways Group
Group	Cochrane Cystic Fibrosis and Genetic
British Paediatric Respiratory Society	Disorders Group
British Society for Gene and Cell	Genomics England
Therapy	MRC Clinical Trials Unit
British Society for Genetic Medicine	National Institute for Health Research
British Society of Medical Genetics	UK Cystic Fibrosis Gene Therapy
British Thoracic Society	Consortium
Chartered Society of Physiotherapy	2 - 112
Cystic Fibrosis Nursing Association	Associated Public Health groups

Provisional stakeholder list for the evaluation of vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

Issue date: September 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>ENT UK</li> <li>Interstitial Lung Diseases Interdisciplinary Network (ILD-IN)</li> <li>National Heart and Lung Institute</li> <li>Neonatal and Paediatric Pharmacists Group (NPPG)</li> <li>Primary Care Respiratory Society UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Paediatrics &amp; Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> <li>UK Cystic Fibrosis Medical Association</li> <li>UK Cystic Fibrosis Pharmacy Group</li> <li>UK Psychosocial Professionals in Cystic Fibrosis Group</li> </ul>	<ul> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
<ul><li>Others</li><li>Department of Health and Social Care</li><li>NHS England</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**


### **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

Issue date: September 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.